The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients. ASH Annual Meeting - Vanazzi, A; Grana, Ch; Laszlo, D (Blood, 2012)
et al.